Indian Immunologicals Introduces India’s First Indigenous Hepatitis A Vaccine
Indian Immunologicals Ltd (IIL), a leading biopharmaceutical company in India and a wholly owned subsidiary of the National Dairy Development Board (NDDB), has made a significant milestone in public health with the launch of Havisure, India’s first indigenously developed Hepatitis A vaccine. This breakthrough vaccine represents a major step forward in the fight against Hepatitis A in the country and is expected to contribute significantly to improving public health.
Understanding Hepatitis A:
Hepatitis A is a highly contagious liver infection that is primarily transmitted through the ingestion of contaminated food or water. The virus spreads through the fecal-oral route, making it essential to practice good hygiene and proper sanitation to prevent its spread. Hepatitis A can lead to various symptoms, including jaundice, fever, fatigue, and abdominal pain. While most cases of the infection resolve on their own, it can lead to severe complications in some individuals, especially those with underlying liver diseases. Vaccination is an effective way to prevent Hepatitis A and reduce its impact on public health.
Development of Havisure:
Havisure, the indigenously developed Hepatitis A vaccine by Indian Immunologicals Ltd, is the result of extensive research and development efforts
by a dedicated team of scientists and researchers. The vaccine has undergone rigorous clinical trials in eight centers, demonstrating its safety and efficacy. The vaccine is comparable to leading multinational vaccines available in the market. The development of Havisure is a testament to India’s commitment to advancing healthcare solutions and achieving self-sufficiency in vaccine production.Role of Havisure in Hepatitis A Prevention:
Havisure is designed to protect against the Hepatitis A virus and is recommended for routine immunization in children. It is a two-dose vaccine, with the first dose given above 12 months of age and the second dose administered at least six months after the first dose. The vaccine is also recommended for individuals at risk of exposure or those traveling to regions with a high prevalence of Hepatitis A. People with occupational risks of infection and those suffering from chronic liver diseases should also consider getting vaccinated against Hepatitis A.
Manufacturing Capabilities:
Indian Immunologicals Ltd has made substantial investments in state-of-the-art manufacturing facilities to scale up production and meet the growing demand for the Hepatitis A vaccine. The company aims to collaborate with healthcare professionals, corporate hospitals, and government agencies to raise awareness about Hepatitis A and the importance of vaccination. By strengthening manufacturing capabilities, Indian Immunologicals Ltd is contributing to the nation’s goal of achieving self-sufficiency in vaccine production.
The launch of Havisure by Indian Immunologicals Ltd marks a significant milestone in India’s public health efforts to combat Hepatitis A. This indigenously developed vaccine offers a safe and effective solution for preventing Hepatitis A, a highly contagious liver infection. By providing access to an affordable, locally produced vaccine, Indian Immunologicals Ltd is contributing to improving public health and strengthening India’s self-sufficiency in vaccine production.
Keywords: Indian Immunologicals, Hepatitis A vaccine, Havisure, indigenously developed, public health, vaccine production, prevention, contagious, liver infection.
